270 related articles for article (PubMed ID: 23867769)
41. The dopamine depleting agent tetrabenazine alters effort-related decision making as assessed by mouse touchscreen procedures.
Yang JH; Presby RE; Rotolo RA; Quiles T; Okifo K; Zorda E; Fitch RH; Correa M; Salamone JD
Psychopharmacology (Berl); 2020 Sep; 237(9):2845-2854. PubMed ID: 32561947
[TBL] [Abstract][Full Text] [Related]
42. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
Chen JJ; Ondo WG; Dashtipour K; Swope DM
Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
[TBL] [Abstract][Full Text] [Related]
43. The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.
Randall PA; Lee CA; Nunes EJ; Yohn SE; Nowak V; Khan B; Shah P; Pandit S; Vemuri VK; Makriyannis A; Baqi Y; Müller CE; Correa M; Salamone JD
PLoS One; 2014; 9(6):e99320. PubMed ID: 24937131
[TBL] [Abstract][Full Text] [Related]
44. Subthalamic and Cortical Local Field Potentials Associated with Pilocarpine-Induced Oral Tremor in the Rat.
Long LL; Podurgiel SJ; Haque AF; Errante EL; Chrobak JJ; Salamone JD
Front Behav Neurosci; 2016; 10():123. PubMed ID: 27378874
[TBL] [Abstract][Full Text] [Related]
45. The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
Ishiwari K; Mingote S; Correa M; Trevitt JT; Carlson BB; Salamone JD
J Neurosci Methods; 2004 Dec; 140(1-2):39-46. PubMed ID: 15589332
[TBL] [Abstract][Full Text] [Related]
46. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
[TBL] [Abstract][Full Text] [Related]
47. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
[TBL] [Abstract][Full Text] [Related]
48. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
[TBL] [Abstract][Full Text] [Related]
49. Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Tseng KY; Kuo TT; Wang V; Huang EY; Ma KH; Olson L; Hoffer BJ; Chen YH
J Parkinsons Dis; 2022; 12(5):1545-1565. PubMed ID: 35599497
[TBL] [Abstract][Full Text] [Related]
50. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
[TBL] [Abstract][Full Text] [Related]
51. Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats.
Miwa H; Koh J; Kajimoto Y; Kondo T
Pharmacol Biochem Behav; 2011 Feb; 97(4):656-9. PubMed ID: 21112351
[TBL] [Abstract][Full Text] [Related]
52. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.
Betz AJ; McLaughlin PJ; Burgos M; Weber SM; Salamone JD
Psychopharmacology (Berl); 2007 Oct; 194(3):347-59. PubMed ID: 17594079
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease.
Gupta S; Sharma B
Brain Res Bull; 2014 Mar; 102():57-68. PubMed ID: 24582883
[TBL] [Abstract][Full Text] [Related]
54. Tetrabenazine Facilitates Exocytosis by Enhancing Calcium-Induced Calcium Release through Ryanodine Receptors.
de Pascual R; Álvarez-Ortego N; de Los Ríos C; Jacob-Mazariego G; García AG
J Pharmacol Exp Ther; 2019 Oct; 371(1):219-230. PubMed ID: 31209099
[TBL] [Abstract][Full Text] [Related]
55. Involvement of adenosine A
Massari CM; Constantino LC; Marques NF; Binder LB; Valle-León M; López-Cano M; Fernández-Dueñas V; Ciruela F; Tasca CI
Purinergic Signal; 2020 Sep; 16(3):379-387. PubMed ID: 32725400
[TBL] [Abstract][Full Text] [Related]
56. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
Guay DR
Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
[TBL] [Abstract][Full Text] [Related]
57. Motor effects of GABA(A) antagonism in globus pallidus: studies of locomotion and tremulous jaw movements in rats.
Wisniecki A; Correa M; Arizzi MN; Ishiwari K; Salamone JD
Psychopharmacology (Berl); 2003 Nov; 170(2):140-9. PubMed ID: 12827348
[TBL] [Abstract][Full Text] [Related]
58. The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making.
Pardo M; Paul NE; Collins-Praino LE; Salamone JD; Correa M
Pharmacol Biochem Behav; 2020 Nov; 198():173035. PubMed ID: 32910928
[TBL] [Abstract][Full Text] [Related]
59. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Lopez S; Turle-Lorenzo N; Johnston TH; Brotchie JM; Schann S; Neuville P; Amalric M
Neuropharmacology; 2008 Sep; 55(4):483-90. PubMed ID: 18625257
[TBL] [Abstract][Full Text] [Related]
60. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
